These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 29361623)

  • 1. [Effect of Pegfilgrastim Primary Prophylactic Administration on Relative Dose Intensity(RDI)in Postoperative Adjuvant Chemotherapy(TC Therapy)for Breast Cancer - A Single-Center, Retrospective Study].
    Nagashima Y; Chijimatsu H; Furuya K; Kondo J; Maeda Y; Somura H; Takemoto N; Yahara N; Abe T; Hayashi H; Kubo H; Yamamoto S; Nagano H
    Gan To Kagaku Ryoho; 2017 Dec; 44(13):2087-2090. PubMed ID: 29361623
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Febrile neutropenia in adjuvant docetaxel and cyclophosphamide (TC) with prophylactic pegfilgrastim in breast cancer patients: a retrospective analysis.
    Ngamphaiboon N; O'Connor TL; Advani PP; Levine EG; Kossoff EB
    Med Oncol; 2012 Sep; 29(3):1495-501. PubMed ID: 21818673
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Safety of Bi-weekly Pegfilgrastim for Dose-dense Chemotherapy-induced Neutropenia in Breast Cancer Patients.
    Mori H; Kubo M; Kai M; Kurata K; Yamada M; Nakamura M
    Anticancer Res; 2018 Jul; 38(7):4381-4386. PubMed ID: 29970577
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of effectiveness of biosimilar filgrastim (Nivestim™), reference Amgen filgrastim and pegfilgrastim in febrile neutropenia primary prevention in breast cancer patients treated with neo(adjuvant) TAC: a non-interventional cohort study.
    Brito M; Esteves S; André R; Isidoro M; Moreira A
    Support Care Cancer; 2016 Feb; 24(2):597-603. PubMed ID: 26111956
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Feasibility of dose-dense epirubicin and cyclophosphamide with subcutaneous pegfilgrastim 3.6 mg support: a single-center prospective study in Japan.
    Morita S; Kikumori T; Tsunoda N; Inaishi T; Adachi Y; Ota A; Shibata M; Matsuoka A; Nakanishi K; Takeuchi D; Mizutani T; Shimokata T; Hayashi H; Maeda O; Ando Y
    Int J Clin Oncol; 2018 Feb; 23(1):195-200. PubMed ID: 28791509
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A pilot study on intermittent every other days of 5-dose Filgrastim compared with single Pegfilgrastim in breast Cancer patients receiving adjuvant Docetaxel, doxorubicin, and cyclophosphamide (TAC) chemotherapy.
    Sohn BS; Jeong JH; Ahn JH; Jung KH; Kim JE; Sohn JH; Koh SJ; Seo JH; Lee KS; Kim SB
    Invest New Drugs; 2020 Jun; 38(3):866-873. PubMed ID: 31728715
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase III placebo-controlled, double-blind, randomized trial of pegfilgrastim to reduce the risk of febrile neutropenia in breast cancer patients receiving docetaxel/cyclophosphamide chemotherapy.
    Kosaka Y; Rai Y; Masuda N; Takano T; Saeki T; Nakamura S; Shimazaki R; Ito Y; Tokuda Y; Tamura K
    Support Care Cancer; 2015 Apr; 23(4):1137-43. PubMed ID: 25576433
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An open-label, randomized, multicenter dose-finding study of once-per-cycle pegfilgrastim versus daily filgrastim in Chinese breast cancer patients receiving TAC chemotherapy.
    Zhang W; Jiang Z; Wang L; Li C; Xia J
    Med Oncol; 2015 May; 32(5):147. PubMed ID: 25820754
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparison of eflapegrastim to pegfilgrastim in the management of chemotherapy-induced neutropenia in patients with early-stage breast cancer undergoing cytotoxic chemotherapy (RECOVER): A Phase 3 study.
    Cobb PW; Moon YW; Mezei K; Láng I; Bhat G; Chawla S; Hasal SJ; Schwartzberg LS
    Cancer Med; 2020 Sep; 9(17):6234-6243. PubMed ID: 32687266
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of pegfilgrastim to support neoadjuvant dose-dense epirubicin and cyclophosphamide chemotherapy in breast cancer.
    Wang X; He Y; Wang T; Xie Y; Li J; Ouyang T; Fan Z
    Support Care Cancer; 2019 Aug; 27(8):3019-3025. PubMed ID: 30607682
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of pegfilgrastim support on day 9 to maintain relative dose intensity of chemotherapy in breast cancer patients receiving a day 1 and 8 CMF regimen.
    Mattioli R; Gridelli C; Castellanos J; Duque A; Falcone A; Mansutti M; Bacon P; Lawrinson S; Skacel T; Casas A
    Clin Transl Oncol; 2009 Dec; 11(12):842-8. PubMed ID: 20045791
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A retrospective evaluation of chemotherapy dose intensity and supportive care for early-stage breast cancer in a curative setting.
    Lyman GH; Dale DC; Tomita D; Whittaker S; Crawford J
    Breast Cancer Res Treat; 2013 Jun; 139(3):863-72. PubMed ID: 23771731
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of filgrastim and pegfilgrastim to prevent neutropenia and maintain dose intensity of adjuvant chemotherapy in patients with breast cancer.
    Kourlaba G; Dimopoulos MA; Pectasides D; Skarlos DV; Gogas H; Pentheroudakis G; Koutras A; Fountzilas G; Maniadakis N
    Support Care Cancer; 2015 Jul; 23(7):2045-51. PubMed ID: 25524005
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Frequency of febrile neutropenia in breast cancer patients receiving epirubicin and docetaxel/paclitaxel with colony-stimulating growth factors: a comparison of filgrastim or lenograstim with pegfilgrastim.
    Schippinger W; Holub R; Dandachi N; Bauernhofer T; Samonigg H
    Oncology; 2006; 70(4):290-3. PubMed ID: 16899982
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Febrile neutropenia incidence and hematological toxicity with the FEC100-docetaxel regimen in the treatment of early-stage breast cancer.
    Cousin S; Le Rhun E; Mailliez A; Fournier C; Bonneterre J
    Bull Cancer; 2012; 99(7-8):75-80. PubMed ID: 22713627
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Feasibility of 4 cycles of docetaxel and cyclophosphamide every 14 days as an adjuvant regimen for breast cancer: a Wisconsin Oncology Network study.
    Burkard ME; Wisinski KB; Njiaju UO; Donohue S; Hegeman R; Stella A; Mansky P; Shah V; Goggins T; Qamar R; Dietrich L; Kim K; Traynor AM; Tevaarwerk AJ
    Clin Breast Cancer; 2014 Jun; 14(3):205-11. PubMed ID: 24342730
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Feasibility and safety of dose-dense docetaxel after conventional epirubicin and cyclophosphamide as adjuvant treatment for early breast cancer patients.
    Sanna G; Pestrin M; Zafarana E; Biagioni C; Cavaciocchi D; Turner N; Di Leo A; Biganzoli L
    Breast; 2013 Oct; 22(5):926-32. PubMed ID: 23707082
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized phase II adjuvant trial of dose-dense docetaxel before or after doxorubicin plus cyclophosphamide in axillary node-positive breast cancer.
    Puhalla S; Mrozek E; Young D; Ottman S; McVey A; Kendra K; Merriman NJ; Knapp M; Patel T; Thompson ME; Maher JF; Moore TD; Shapiro CL
    J Clin Oncol; 2008 Apr; 26(10):1691-7. PubMed ID: 18316792
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Feasibility of prior administration of cyclophosphamide in TC combination treatment.
    Abe H; Kawai Y; Mori T; Cho H; Kubota Y; Umeda T; Tani T
    Breast Cancer; 2014 Mar; 21(2):202-7. PubMed ID: 22696251
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Once-per-cycle pegfilgrastim in breast cancer patients treated with docetaxel/epidoxorubicin/cyclophosphamide.
    Montella L; Addeo R; Guarrasi R; Cennamo G; Faiola V; Capasso E; Caraglia M; Del Prete S
    Eur J Cancer Care (Engl); 2010 Mar; 19(2):200-4. PubMed ID: 19552732
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.